Barrier Therapeutics, Inc., a pharmaceutical company that develops and markets dermatology products, today announced positive results from its completed Phase 2b dose ranging study for its novel oral antifungal product candidate pramiconazole (previously known as Azoline). Pramiconazole met the primary endpoint of effectively treating tinea versicolor, a common skin fungal infection ...
From: biz.yahoo.com
Pramiconazole) Dose Ranging Study in Tinea Versicolor Meets Primary and ...
Posted by Ruslan Abuzant at 6:13 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment